EUROFINS SCIENT Long Term Debt 2018-2024 | ERFSF
EUROFINS SCIENT long term debt from 2018 to 2024. Long term debt can be defined as the sum of all long term debt fields.
- EUROFINS SCIENT long term debt for the quarter ending June 30, 2024 was $3.412B, a 2.38% increase year-over-year.
- EUROFINS SCIENT long term debt for 2023 was $3.599B, a 9.78% increase from 2022.
- EUROFINS SCIENT long term debt for 2022 was $3.279B, a 10.83% increase from 2021.
- EUROFINS SCIENT long term debt for 2021 was $2.958B, a 11.23% decline from 2020.
| EUROFINS SCIENT Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2023 | $3,599 |
| 2022 | $3,279 |
| 2021 | $2,958 |
| 2020 | $3,332 |
| 2019 | $3,457 |
| 2018 | $3,267 |
| 2017 | $1,879 |
| 2016 | $0 |
| 2015 | $0 |
| EUROFINS SCIENT Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2023-06-30 | $3,412 |
| 2022-12-31 | $3,279 |
| 2021-12-31 | $2,958 |
| 2021-06-30 | $3,045 |
| 2020-12-31 | $3,332 |
| 2020-06-30 | $3,228 |
| 2019-12-31 | $3,457 |
| 2019-06-30 | $2,995 |
| 2018-12-31 | $3,267 |
| 2018-06-30 | $1,993 |
| 2017-12-31 | $1,879 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.158B | $7.522B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $136.657B | 25.63 |
| Elevance Health (ELV) | United States | $88.114B | 11.37 |
| CVS Health (CVS) | United States | $76.496B | 9.51 |
| Cencora (COR) | United States | $55.428B | 19.28 |
| DiDi Global (DIDIY) | China | $22.215B | 33.71 |
| Natera (NTRA) | United States | $20.400B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.620B | 13.36 |
| CochLear (CHEOY) | Australia | $11.298B | 0.00 |
| Doximity (DOCS) | United States | $10.912B | 50.83 |
| Revvity (RVTY) | United States | $10.655B | 18.34 |
| ICON (ICLR) | Ireland | $10.552B | 9.81 |
| Viatris (VTRS) | United States | $10.317B | 3.54 |
| Avantor (AVTR) | United States | $8.750B | 12.71 |
| Medpace Holdings (MEDP) | United States | $8.519B | 22.63 |
| HealthEquity (HQY) | United States | $8.446B | 41.55 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.822B | 13.37 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.185B | 38.74 |
| Bausch + Lomb (BLCO) | Canada | $4.171B | 24.58 |
| Sotera Health (SHC) | United States | $3.616B | 20.55 |
| Surgery Partners (SGRY) | United States | $3.029B | 39.39 |
| Alignment Healthcare (ALHC) | United States | $2.948B | 0.00 |
| Concentras Parent (CON) | United States | $2.925B | 16.90 |
| Organon (OGN) | United States | $2.280B | 2.42 |
| Ardent Health Partners (ARDT) | United States | $2.179B | 9.29 |
| Progyny (PGNY) | United States | $1.882B | 41.42 |
| Premier (PINC) | United States | $1.877B | 14.24 |
| GeneDx Holdings (WGS) | United States | $1.815B | 69.90 |
| PACS (PACS) | United States | $1.625B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.432B | 28.64 |
| Pediatrix Medical (MD) | United States | $1.278B | 9.73 |
| Teladoc Health (TDOC) | United States | $1.272B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.059B | 0.00 | |
| Agilon Health (AGL) | United States | $1.056B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| Nutex Health (NUTX) | United States | $0.967B | 14.61 |
| CareDx (CDNA) | United States | $0.896B | 14.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.857B | 8.02 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.681B | 4.59 |
| InnovAge Holding (INNV) | United States | $0.570B | 0.00 |
| Enhabit (EHAB) | United States | $0.545B | 44.83 |
| Auna S.A (AUNA) | Luxembourg | $0.514B | 13.63 |
| Sonida Senior Living (SNDA) | United States | $0.493B | 0.00 |
| LifeMD (LFMD) | United States | $0.439B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.367B | 0.00 |
| SBC Medicals (SBC) | United States | $0.361B | 0.00 |
| Oncology Institute (TOI) | United States | $0.230B | 0.00 |
| Beauty Health (SKIN) | United States | $0.217B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.204B | 0.00 |
| DocGo (DCGO) | United States | $0.143B | 23.33 |
| Sera Prognostics (SERA) | United States | $0.090B | 0.00 |
| KindlyMD (KDLY) | United States | $0.083B | 0.00 |
| So-Young (SY) | China | $0.083B | 0.00 |
| OncoCyte (OCX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.049B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.033B | 0.00 |
| Biodesix (BDSX) | United States | $0.032B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |